REDWOOD CITY, Calif.,
Sept. 4, 2019 /PRNewswire/ -- Bolt
Biotherapeutics, Inc., a private biotechnology company focused on
unleashing the power of the immune system to treat cancer, today
announced that it has appointed Randall
Schatzman, Ph.D. to the position of chief executive officer
and as a member of Bolt's board of directors. Dr. Schatzman brings
over 30 years of biotech leadership experience to Bolt and most
recently served as president and CEO of Alder BioPharmaceuticals,
Inc. where he successfully led the company from inception through
registration-enabling activities including positive Phase 3 trials
and significant fund raising.
"I am very pleased to welcome Randy as our chief executive
officer," said Peter Moldt, of Novo
Ventures and executive chairman of the board of Bolt
Biotherapeutics. "We believe our ISAC technology has great
potential and look forward to Randy's expert leadership to
successfully advance Bolt's programs and therapeutic
candidates."
"ISACs represent an important evolution of cancer
immunotherapies with the potential to have a profound impact on a
significant number of cancer patients, and I'm excited to have the
opportunity to play a role in their development," stated Dr.
Schatzman. "I am joining an experienced cancer immunotherapy team
which includes alumni of the industry's premier cancer therapeutics
companies and Ed Engleman, M.D.,
Bolt founder, and inventor of the technology underlying the
first-ever FDA-approved immunotherapy. The Bolt team is progressing
on a strategy to quickly demonstrate the efficacy and safety of our
novel technology and expect to enter the clinic in the first half
of next year. Bolt's impressive preclinical data
support optimism for our ISACs by demonstrating not only
complete eradication of hard to treat tumors but also establishment
of immunological memory which enables prevention of tumor
re-establishment, promising improved durability of clinical
response for patients."
About Randall Schatzman,
Ph.D.
Dr. Randall Schatzman
joins Bolt Biotherapeutics with over 30 years of biotechnology
experience. Prior to Bolt, Dr. Schatzman was president and CEO,
co-founder and board member of Alder BioPharmaceuticals, Inc.
(Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific
team co-founded Alder in 2004 and led the company through the
discovery and patenting of two monoclonal antibody therapeutics:
eptinezumab, now in registration at FDA for migraine prevention and
clazakizumab, being developed by Vitaeris for treatment of
antibody-mediated kidney allograft failure. Prior to co-founding
Alder, Dr. Schatzman was senior vice president of discovery
research at Celltech R&D where the team discovered romosozumab
which was subsequently licensed to Amgen in a 50/50 partnership.
Prior to joining Celltech, he was at Syntex/Roche Bioscience where
he served as preclinical team leader for Cytovene and team leader
for Valcyte, both of which are now currently marketed drugs. Dr.
Schatzman received his Ph.D. in Molecular Pharmacology from
Emory University before completing an
American Cancer Society postdoctoral fellowship in the laboratory
of J. Michael Bishop at the
University of California, San
Francisco. Dr. Schatzman is an inventor on over 30 issued
patents and is an author on more than 40 peer reviewed scientific
publications.
About Bolt Biotherapeutics' Immune-Stimulating Antibody
Conjugate (ISAC) Platform Technology
The Boltbody™ platform
consists of Immune-Stimulating Antibody Conjugates (ISAC) that
harness the ability of TLR agonists to convert cold tumors into
immunologically hot tumors thereby illuminating tumors to the
immune system allowing them to be invaded by tumor killing cells.
Boltbody™ ISACs have demonstrated the ability to eliminate tumors
following systemic administration in preclinical models and have
also led to the development of immunological memory, which is
predicted to translate into more durable clinical responses for
patients.
About Bolt Biotherapeutics
Bolt Biotherapeutics,
Inc., based in the San Francisco Bay
Area, is a private biotechnology company developing
Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new
class of immuno-oncology therapeutics that have eliminated tumors
following systemic administration in preclinical studies and
results in the development of immunological memory, which may lead
to more durable clinical responses for patients. Bolt's technology
is appropriate for a broad spectrum of antibodies targeting tumor
antigens expressed on all types of cancer and therefore applicable
to many types of patients, including those who are refractory to
the current generation of checkpoint inhibitors. The company is led
by a team with extensive oncology drug discovery and development
experience. Bolt was founded by Dr. Ed
Engleman, and its platform is based on technology
exclusively licensed from Stanford
University. The company is financed by world-class
investors including Novo Holdings, Pivotal bioVenture Partners,
Vivo Capital and Nan Fung Life Sciences. For more information about
Bolt Biotherapeutics, please visit www.boltbio.com.
Contact:
Jennifer Williams
Cook Williams Communications, Inc.
360-668-3701
jennifer@cwcomm.org
View original
content:http://www.prnewswire.com/news-releases/bolt-biotherapeutics-appoints-veteran-executive-randall-schatzman-as-ceo-to-lead-the-next-phase-of-growth-300910432.html
SOURCE Bolt Biotherapeutics, Inc.
